bupropion has been researched along with Weight Loss in 62 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Weight Loss: Decrease in existing BODY WEIGHT.
Excerpt | Relevance | Reference |
---|---|---|
" The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity." | 9.51 | Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. ( Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO, 2022) |
" The new combination of naltrexone and bupropion sustained release (NB) has proved to be effective for weight loss among obese patients." | 9.41 | An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. ( Aloi, M; Arturi, F; Calabrò, G; Carbone, EA; Caroleo, M; Condoleo, F; de Filippis, R; Rania, M; Segura-Garcia, C; Staltari, FA, 2021) |
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks." | 9.24 | Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017) |
"To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight-related risk factors in overweight and obese participants." | 9.17 | A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013) |
"Bupropion was well tolerated and produced significantly greater-albeit quite modest-short-term weight loss in overweight and obese women with BED." | 9.17 | Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013) |
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs." | 9.17 | Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013) |
"A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity." | 9.14 | Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. ( Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA, 2010) |
"Our objective was to determine whether opioid receptor antagonism (naltrexone) plus pro-opiomelanocortin activation (bupropion) causes greater weight loss than placebo or monotherapy." | 9.14 | Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. ( Cowley, MA; Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Tollefson, G, 2009) |
"In this short-term, open-label, preliminary trial, combination treatment of zonisamide and bupropion resulted in more weight loss than treatment with zonisamide alone." | 9.12 | Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007) |
"To examine the effectiveness of bupropion in reducing bodyweight gained during treatment with olanzapine." | 9.12 | Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. ( Foust, MS; Gadde, KM; Zhang, W, 2006) |
"Bupropion SR in combination with a 500 kcal/d-deficit diet facilitated weight loss." | 9.10 | Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002) |
"To critically examine the efficacy of bupropion SR for weight loss." | 9.10 | Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. ( Anderson, JW; Fujioka, K; Gadde, KM; Greenway, FL; McKenney, J; O'Neil, PM, 2002) |
"Subjects receiving bupropion achieved greater mean weight loss (last-observation-carried-forward analysis) over the first 8 weeks of the study (p = 0." | 9.09 | Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. ( Drezner, MK; Gadde, KM; Krishnan, KR; Logue, EJ; Maner, LG; Parker, CB; Wagner, HR, 2001) |
"Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification." | 8.93 | Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. ( Apovian, CM, 2016) |
"The mechanism of action of the combination therapy, naltrexone/bupropion (NB), for obesity has not been fully described to date." | 8.90 | Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. ( Billes, SK; Cowley, MA; Sinnayah, P, 2014) |
"This review examines the safety and antiobesity effects of naltrexone and bupropion alone and in combination." | 8.90 | Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. ( Bello, NT; Verpeut, JL, 2014) |
"Naltrexone/bupropion is an investigational combination for weight loss and maintenance in patients who are obese or have a BMI ≥ 27 kg/m(2) with comorbid diabetes, hypertension or hyperlipidemia." | 8.87 | Naltrexone/bupropion: an investigational combination for weight loss and maintenance. ( Gwinn, KM; Hurren, KM; Makowski, CT, 2011) |
" Appropriate patient management should address the mild sympathomimetic effect of bupropion, although the FDA has required that a cardiovascular outcomes study be conducted preapproval to determine the effects of long-term use of naltrexone/bupropion in an overweight/obese population." | 8.87 | Combination therapy with naltrexone and bupropion for obesity. ( Billes, SK; Greenway, FL, 2011) |
" While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion." | 8.85 | Naltrexone for the treatment of obesity: review and update. ( Fujioka, K; Lee, MW, 2009) |
"Both bupropion and naltrexone have been shown individually to induce weight loss." | 8.85 | Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. ( Chau, DL; Nguyen, L; Nguyen, Q; Plodkowski, RA; St Jeor, S; Sundaram, U, 2009) |
"Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone." | 8.85 | Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. ( Padwal, R, 2009) |
"To investigate the changes of circulating levels of all proglucagon-derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide (3 mg) or naltrexone/bupropion (32/360 mg), and to explore the association between induced changes in postprandial PGDP levels and body composition, as well as metabolic variables, after 3 and 6 months on treatment." | 8.31 | Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long ( Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K, 2023) |
"Weight loss is associated with improved quality of life in some, but not all, weight loss trials." | 6.80 | Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. ( Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL, 2015) |
"The prevalence of obesity is growing rapidly worldwide, and therefore there is a need for effective treatment strategies." | 6.47 | Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? ( Hatzitolios, AI; Katsiki, N; Mikhailidis, DP, 2011) |
"Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit." | 6.44 | Bupropion for weight reduction. ( Gadde, KM; Xiong, GL, 2007) |
" The authors tested the effectiveness of naltrexone-bupropion and behavioral weight loss therapy (BWL), alone and combined, for binge-eating disorder comorbid with obesity." | 5.51 | Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. ( Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO, 2022) |
" The new combination of naltrexone and bupropion sustained release (NB) has proved to be effective for weight loss among obese patients." | 5.41 | An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. ( Aloi, M; Arturi, F; Calabrò, G; Carbone, EA; Caroleo, M; Condoleo, F; de Filippis, R; Rania, M; Segura-Garcia, C; Staltari, FA, 2021) |
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks." | 5.24 | Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017) |
"Bupropion was well tolerated and produced significantly greater-albeit quite modest-short-term weight loss in overweight and obese women with BED." | 5.17 | Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013) |
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs." | 5.17 | Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013) |
"To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight-related risk factors in overweight and obese participants." | 5.17 | A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013) |
" Here, we explore combination therapy with bupropion (BUP), a putative stimulator of melanocortin pathways, and an opioid antagonist, naltrexone (NAL), to antagonize an inhibitory feedback loop that limits sustained weight reduction." | 5.14 | Rational design of a combination medication for the treatment of obesity. ( Anderson, JW; Atkinson, RL; Cowley, MA; Dunayevich, E; Fujioka, K; Gadde, KM; Greenway, FL; Gupta, AK; Guttadauria, M; O'Neil, P; Schumacher, D; Smith, D; Tollefson, GD; Weber, E; Whitehouse, MJ, 2009) |
"Our objective was to determine whether opioid receptor antagonism (naltrexone) plus pro-opiomelanocortin activation (bupropion) causes greater weight loss than placebo or monotherapy." | 5.14 | Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. ( Cowley, MA; Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Tollefson, G, 2009) |
"A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity." | 5.14 | Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. ( Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA, 2010) |
"To examine the effectiveness of bupropion in reducing bodyweight gained during treatment with olanzapine." | 5.12 | Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. ( Foust, MS; Gadde, KM; Zhang, W, 2006) |
"In this short-term, open-label, preliminary trial, combination treatment of zonisamide and bupropion resulted in more weight loss than treatment with zonisamide alone." | 5.12 | Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. ( Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM, 2007) |
"Bupropion SR in combination with a 500 kcal/d-deficit diet facilitated weight loss." | 5.10 | Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. ( Allison, DB; Brewer, ER; Buaron, KS; Gadde, KM; Haight, B; Jain, AK; Jamerson, BD; Kaplan, RA; Leadbetter, RA; Metz, A; Richard, N; Wadden, TA, 2002) |
"To critically examine the efficacy of bupropion SR for weight loss." | 5.10 | Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. ( Anderson, JW; Fujioka, K; Gadde, KM; Greenway, FL; McKenney, J; O'Neil, PM, 2002) |
"Subjects receiving bupropion achieved greater mean weight loss (last-observation-carried-forward analysis) over the first 8 weeks of the study (p = 0." | 5.09 | Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. ( Drezner, MK; Gadde, KM; Krishnan, KR; Logue, EJ; Maner, LG; Parker, CB; Wagner, HR, 2001) |
"Four new medicines-liraglutide, lorcaserin, bupropion/naltrexone, and phentermine/topiramate-have been recently added to the pharmacological arsenal for obesity treatment and could represent important tools to manage this epidemic disease." | 5.01 | Gender-related issues in the pharmacology of new anti-obesity drugs. ( Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M, 2019) |
" The aim of the present review is to summarize the current data on the eff ects of antiobesity drugs approved in Europe (orlistat, liraglutide 3 mg od and naltrexone/bupropion) on weight loss in patients with PCOS and to discuss their impact on the endocrine, reproductive and metabolic abnormalities of this population." | 4.98 | The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. ( Chatzis, P; Dinas, K; Makris, V; Pratilas, GC; Sotiriadis, A; Tziomalos, K, 2018) |
" Phentermine/topiramate ER appeared to have the best overall average weight loss from baseline as well as highest percentages of patients achieving both ≥5% and ≥10% weight loss benchmarks, followed second by naltrexone/bupropion, and then liraglutide, with lorcaserin showing the lowest rates." | 4.93 | A Comparison of New Pharmacological Agents for the Treatment of Obesity. ( Megyeri, J; Nuffer, W; Trujillo, JM, 2016) |
"Contrave(®) is a combination of naltrexone hydrochloride extended release and bupropion hydrochloride extended release for the treatment of obesity, and is used with lifestyle modification." | 4.93 | Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. ( Apovian, CM, 2016) |
"The mechanism of action of the combination therapy, naltrexone/bupropion (NB), for obesity has not been fully described to date." | 4.90 | Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. ( Billes, SK; Cowley, MA; Sinnayah, P, 2014) |
"This review examines the safety and antiobesity effects of naltrexone and bupropion alone and in combination." | 4.90 | Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. ( Bello, NT; Verpeut, JL, 2014) |
"A short overview of new drugs approved for the treatment of obesity (lorcaserin, phentermine/topiramate combination) as well as those with a perspective for approval as antiobesity drugs (cetilistat, naltrexone/bupropion combination, liraglutide) is presented." | 4.90 | Overview of new antiobesity drugs. ( Hainer, V, 2014) |
"Naltrexone/bupropion is an investigational combination for weight loss and maintenance in patients who are obese or have a BMI ≥ 27 kg/m(2) with comorbid diabetes, hypertension or hyperlipidemia." | 4.87 | Naltrexone/bupropion: an investigational combination for weight loss and maintenance. ( Gwinn, KM; Hurren, KM; Makowski, CT, 2011) |
"Contrave is an investigational fixed-dose combination drug of naltrexone and bupropion currently in Phase III clinical trials for the treatment of obesity." | 4.87 | ACS chemical neuroscience molecule spotlight on contrave. ( Mercer, SL, 2011) |
" Appropriate patient management should address the mild sympathomimetic effect of bupropion, although the FDA has required that a cardiovascular outcomes study be conducted preapproval to determine the effects of long-term use of naltrexone/bupropion in an overweight/obese population." | 4.87 | Combination therapy with naltrexone and bupropion for obesity. ( Billes, SK; Greenway, FL, 2011) |
"Both bupropion and naltrexone have been shown individually to induce weight loss." | 4.85 | Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. ( Chau, DL; Nguyen, L; Nguyen, Q; Plodkowski, RA; St Jeor, S; Sundaram, U, 2009) |
" While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion." | 4.85 | Naltrexone for the treatment of obesity: review and update. ( Fujioka, K; Lee, MW, 2009) |
"Contrave, under development by Orexigen Therapeutics Inc for the potential treatment of obesity, is an oral, sustained-release combination of the dopamine and norepinephrine reuptake antagonist bupropion and the opioid antagonist naltrexone." | 4.85 | Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. ( Padwal, R, 2009) |
"To investigate the changes of circulating levels of all proglucagon-derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide (3 mg) or naltrexone/bupropion (32/360 mg), and to explore the association between induced changes in postprandial PGDP levels and body composition, as well as metabolic variables, after 3 and 6 months on treatment." | 4.31 | Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long ( Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K, 2023) |
" This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin agents." | 4.02 | Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. ( Barakat, M; Blavignac, J; Burrows, M; Camacho, F; Christensen, RAG; Gould, E; Kamran, E; Wharton, S; Yin, P, 2021) |
"The recent approval of liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/topiramate extended-release, brings the number of medications for long-term weight loss to 5 (including orlistat)." | 3.83 | Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. ( Braverman-Panza, J; Fujioka, K, 2016) |
" Importantly, the appetite suppressant-induced weight loss and locomotion were markedly reduced by intragastric (and intra-NAc shell) infusions of dopamine antagonists SCH-23390 (D1 receptor) or raclopride (D2 receptor)." | 3.81 | D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell. ( Elias, D; Gutierrez, R; Kalyanasundar, B; Luna, A; Moreno, MG; Perez, CI; Simon, SA; Solorio, J, 2015) |
"The significant weight loss observed with combination naltrexone-sustained release (SR) 32 mg and bupropion SR 360 mg (NB32) therapy is thought to be due, in part, to bupropion stimulation of hypothalamic pro-opiomelanocortin (POMC) neurons, and naltrexone blockade of opioid receptor-mediated POMC autoinhibition, but the neurobiological mechanisms are not fully understood." | 3.80 | Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. ( Caparelli, EC; Dunayevich, E; Telang, F; Tomasi, D; Volkow, ND; Wang, GJ; Wang, R, 2014) |
"Bupropion (BUP) is a dopamine (DA) and norepinephrine (NE) reuptake inhibitor that causes mild weight loss in obese adults." | 3.74 | Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis. ( Billes, SK; Cowley, MA, 2008) |
"Weight loss is associated with improved quality of life in some, but not all, weight loss trials." | 2.80 | Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. ( Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL, 2015) |
" The purpose of the study is to determine the relationship between these treatments and the risk of major cardiovascular adverse events (MACE)." | 2.72 | Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses. ( Aguilar-Salinas, C; Benchimol, A; Bonilha, I; Carvalho, LSF; Cercato, C; Geloneze, B; Hohl, A; Luchiari, B; Moura, F; Nadruz, W; Sposito, AC, 2021) |
" However, they are costly and may have adverse effects in some individuals." | 2.72 | Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? ( Lee, SY; Tak, YJ, 2021) |
" Thus, if following the appropriate guidelines according to package labels, the practitioner can feel safe in prescribing these medications." | 2.52 | Safety and tolerability of medications approved for chronic weight management. ( Fujioka, K, 2015) |
"The prevalence of obesity is rising worldwide, with the U." | 2.48 | Recent advancements in drug treatment of obesity. ( Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J, 2012) |
"The prevalence of obesity is growing rapidly worldwide, and therefore there is a need for effective treatment strategies." | 2.47 | Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? ( Hatzitolios, AI; Katsiki, N; Mikhailidis, DP, 2011) |
"Bupropion is a norepinephrine and dopamine uptake inhibitor that has been available for several years for the treatment of depression and aiding smokers to quit." | 2.44 | Bupropion for weight reduction. ( Gadde, KM; Xiong, GL, 2007) |
"Mean (SD) weight loss was 5." | 1.62 | Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study. ( Chung, WK; Febres, G; Holleran, S; Korner, J; LeDuc, CA; Mullally, JA; Ramakrishnan, R; Reid, TJ, 2021) |
"Maintaining weight loss is extremely difficult due to the neuro-endocrine dysregulations that stimulate the body to return to the previous, increased, weight." | 1.62 | [Pharmacotherapy for obesity]. ( Abawi, O; van den Akker, ELT; van der Valk, ES; van der Voorn, B; van Rossum, EFC; Welling, MS, 2021) |
"Obesity is a chronic disease universally defined as an excess of adipose tissue resulting in body mass index (BMI) > 30." | 1.46 | Obesity Epidemic: Pharmaceutical Weight Loss. ( Curry, SA, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 12 (19.35) | 29.6817 |
2010's | 38 (61.29) | 24.3611 |
2020's | 12 (19.35) | 2.80 |
Authors | Studies |
---|---|
Grilo, CM | 2 |
Lydecker, JA | 1 |
Fineberg, SK | 1 |
Moreno, JO | 1 |
Ivezaj, V | 1 |
Gueorguieva, R | 1 |
BouSaba, J | 1 |
Vosoughi, K | 1 |
Dilmaghani, S | 1 |
Prokop, LJ | 1 |
Camilleri, M | 1 |
Stefanakis, K | 1 |
Kokkinos, A | 1 |
Argyrakopoulou, G | 1 |
Konstantinidou, SK | 1 |
Simati, S | 1 |
Kouvari, M | 1 |
Kumar, A | 1 |
Kalra, B | 1 |
Kumar, M | 1 |
Bontozoglou, N | 1 |
Kyriakopoulou, K | 1 |
Mantzoros, CS | 1 |
Thomas, B | 2 |
Lindblad, AJ | 2 |
Luu, T | 2 |
Paige, A | 2 |
Carbone, EA | 1 |
Caroleo, M | 1 |
Rania, M | 1 |
Calabrò, G | 1 |
Staltari, FA | 1 |
de Filippis, R | 1 |
Aloi, M | 1 |
Condoleo, F | 1 |
Arturi, F | 1 |
Segura-Garcia, C | 1 |
Milano, W | 1 |
De Biasio, V | 1 |
Di Munzio, W | 1 |
Foggia, G | 1 |
Capasso, A | 1 |
Mullally, JA | 1 |
Chung, WK | 1 |
LeDuc, CA | 1 |
Reid, TJ | 1 |
Febres, G | 1 |
Holleran, S | 1 |
Ramakrishnan, R | 1 |
Korner, J | 1 |
Tak, YJ | 1 |
Lee, SY | 1 |
van Rossum, EFC | 1 |
Welling, MS | 1 |
van der Voorn, B | 1 |
van der Valk, ES | 1 |
Abawi, O | 1 |
van den Akker, ELT | 1 |
Sposito, AC | 1 |
Bonilha, I | 1 |
Luchiari, B | 1 |
Benchimol, A | 1 |
Hohl, A | 1 |
Moura, F | 1 |
Cercato, C | 1 |
Geloneze, B | 1 |
Nadruz, W | 1 |
Aguilar-Salinas, C | 1 |
Carvalho, LSF | 1 |
Wharton, S | 1 |
Yin, P | 1 |
Burrows, M | 1 |
Gould, E | 1 |
Blavignac, J | 1 |
Christensen, RAG | 1 |
Kamran, E | 1 |
Camacho, F | 1 |
Barakat, M | 1 |
Dalton, M | 1 |
Finlayson, G | 1 |
Walsh, B | 3 |
Halseth, AE | 2 |
Duarte, C | 1 |
Blundell, JE | 1 |
Wilding, JPH | 1 |
Cataldi, M | 1 |
Muscogiuri, G | 1 |
Savastano, S | 1 |
Barrea, L | 1 |
Guida, B | 1 |
Taglialatela, M | 1 |
Colao, A | 1 |
Chatzis, P | 1 |
Tziomalos, K | 1 |
Pratilas, GC | 1 |
Makris, V | 1 |
Sotiriadis, A | 1 |
Dinas, K | 1 |
Apovian, CM | 2 |
Aronne, L | 1 |
Rubino, D | 1 |
Still, C | 1 |
Wyatt, H | 1 |
Burns, C | 3 |
Kim, D | 2 |
Dunayevich, E | 7 |
Smith, SR | 1 |
Fujioka, K | 12 |
Gupta, AK | 3 |
Billes, SK | 4 |
Greenway, FL | 8 |
White, MA | 1 |
Wang, GJ | 1 |
Tomasi, D | 1 |
Volkow, ND | 1 |
Wang, R | 1 |
Telang, F | 1 |
Caparelli, EC | 1 |
Hollander, P | 1 |
Plodkowski, R | 2 |
Greenway, F | 1 |
Bays, H | 1 |
Klassen, P | 2 |
Sinnayah, P | 1 |
Cowley, MA | 4 |
Verpeut, JL | 1 |
Bello, NT | 1 |
Hainer, V | 1 |
Citrome, L | 2 |
Kalyanasundar, B | 1 |
Perez, CI | 1 |
Luna, A | 1 |
Solorio, J | 1 |
Moreno, MG | 1 |
Elias, D | 1 |
Simon, SA | 1 |
Gutierrez, R | 1 |
Kolotkin, RL | 1 |
Chen, S | 1 |
Gilder, K | 3 |
Nuffer, W | 1 |
Trujillo, JM | 1 |
Megyeri, J | 1 |
O'Neil, PM | 3 |
Hong, K | 1 |
Herrmann, K | 1 |
Dybala, C | 1 |
Lam, H | 1 |
Foreyt, JP | 2 |
Braverman-Panza, J | 1 |
Stefanidis, A | 1 |
Man Lee, CC | 1 |
Brown, WA | 1 |
Oldfield, BJ | 1 |
Halseth, A | 1 |
Shan, K | 1 |
Curry, SA | 1 |
Whitehouse, MJ | 1 |
Guttadauria, M | 3 |
Anderson, JW | 2 |
Atkinson, RL | 1 |
Gadde, KM | 7 |
O'Neil, P | 1 |
Schumacher, D | 1 |
Smith, D | 1 |
Tollefson, GD | 1 |
Weber, E | 1 |
Plodkowski, RA | 2 |
Nguyen, Q | 1 |
Sundaram, U | 1 |
Nguyen, L | 1 |
Chau, DL | 1 |
St Jeor, S | 1 |
Lee, MW | 1 |
Padwal, R | 1 |
Tollefson, G | 1 |
Erickson, J | 2 |
Kaplan, LM | 1 |
Wadden, TA | 2 |
Foster, GD | 1 |
Hill, JO | 1 |
Klein, S | 1 |
Perri, MG | 1 |
Pi-Sunyer, FX | 1 |
Rock, CL | 1 |
Erickson, JS | 1 |
Maier, HN | 1 |
Kim, DD | 2 |
Mudaliar, S | 1 |
Katsiki, N | 1 |
Hatzitolios, AI | 1 |
Mikhailidis, DP | 1 |
Calandra, C | 1 |
Russo, RG | 1 |
Luca, M | 1 |
Makowski, CT | 1 |
Gwinn, KM | 1 |
Hurren, KM | 1 |
Hiatt, WR | 1 |
Thomas, A | 1 |
Goldfine, AB | 1 |
Mercer, SL | 1 |
Carter, R | 1 |
Mouralidarane, A | 1 |
Ray, S | 1 |
Soeda, J | 1 |
Oben, J | 1 |
Jain, AK | 1 |
Kaplan, RA | 1 |
Allison, DB | 1 |
Brewer, ER | 1 |
Leadbetter, RA | 1 |
Richard, N | 1 |
Haight, B | 1 |
Jamerson, BD | 1 |
Buaron, KS | 1 |
Metz, A | 1 |
Zhang, W | 1 |
Foust, MS | 2 |
Xiong, GL | 1 |
Yonish, GM | 1 |
Wagner, HR | 2 |
Parker, CB | 1 |
Maner, LG | 1 |
Logue, EJ | 1 |
Drezner, MK | 1 |
Krishnan, KR | 1 |
McKenney, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00567255] | Phase 3 | 1,496 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder[NCT00414167] | Phase 2/Phase 3 | 61 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
Naltrexone Sustained Release (SR) 32 mg and Bupropion Sustained Release (SR) 360 mg Combination Therapy in Functional Magnetic Resonance Imaging (fMRI) Changes in Overweight or Obese Subjects[NCT00711477] | Phase 2 | 46 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus[NCT00474630] | Phase 3 | 505 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)[NCT01764386] | Phase 3 | 242 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation[NCT00419731] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2006-11-30 | Recruiting | ||
The Beef WISE Study: Beef's Role in Weight Improvement, Satisfaction, and Energy[NCT02627105] | 120 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion SR and Placebo in Subjects With Obesity Participating in a Behavior Modification Program[NCT00456521] | Phase 3 | 793 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00532779] | Phase 3 | 1,742 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet[NCT02154230] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to failure to enroll) | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB32 | -6.40 |
Placebo | -1.23 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 27.27 |
Placebo | 7.02 |
"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 50.48 |
Placebo | 17.11 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB32 | 0.20 |
Placebo | -0.67 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -2.11 |
Placebo | -1.73 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | 1.19 |
Placebo | -1.40 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -14.14 |
Placebo | -0.50 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -4.36 |
Placebo | 0.00 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -7.32 |
Placebo | -1.36 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -2.68 |
Placebo | -2.20 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -3.20 |
Placebo | -3.18 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -9.38 |
Placebo | -1.14 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -16.44 |
Placebo | -4.15 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -0.23 |
Placebo | -0.28 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 9.94 |
Placebo | 6.17 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -18.32 |
Placebo | -11.09 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB32 | -0.93 |
Placebo | -1.23 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | cm (Least Squares Mean) |
---|---|
NB32 | -6.16 |
Placebo | -2.74 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB32 | -6.45 |
Placebo | -1.89 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 55.64 |
Placebo | 17.54 |
(NCT00414167)
Timeframe: One week (at post treatment)
Intervention | episodes/week (Mean) |
---|---|
Bupropion | 0.8 |
Placebo | 1.0 |
Percent loss in Body Mass Index (NCT00414167)
Timeframe: 8 weeks (baseline and 8 weeks)
Intervention | Percent loss (Mean) |
---|---|
Bupropion | 1.8 |
Placebo | 0.6 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -13.55 |
Placebo | -4.14 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating A subscale (clearly labeled emotions) consisted of 9 items and the scores ranged from 9 (better outcome) to 45 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -1.16 |
Placebo | 0.48 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Emotional Eating B subscale (diffuse emotions) consisted of 4 items and the scores ranged from 4 (better outcome) to 20 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -0.90 |
Placebo | 0.45 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The External Eating subscale consisted of 10 items and the scores ranged from 10 (better outcome) to 50 (worse outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -2.64 |
Placebo | -0.16 |
The Dutch Eating Behavior Questionnaire is a 33-item self-report measure designed to assess the type of eating behavior and is organized into 3 subscales (emotional eating, externally-induced eating, and restrained eating). Subjects rated the frequency of their eating behaviors using a 5-point scale, where 1=never, 2=seldom, 3=sometimes, 4=often, and 5=very often. The Restrained Eating subscale consisted of 10 items and the scores ranged from 10 (worse outcome) to 50 (better outcome). (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 1.47 |
Placebo | 1.87 |
(NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB32 | -0.99 |
Placebo | -0.43 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.42 |
NB32 | 0.16 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.16 |
NB32 | 0.60 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.79 |
NB32 | 0.21 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.16 |
NB32 | 0.30 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.35 |
NB32 | 0.34 |
Assessment of differences in brain activation in response to food cues before and after 4 weeks of treatment in subjects receiving NB or placebo. (NCT00711477)
Timeframe: Baseline, 4 weeks
Intervention | percent activation (Mean) |
---|---|
Placebo | -0.56 |
NB32 | 0.74 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 18.49 |
Placebo | 5.66 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB32 | -1.06 |
Placebo | -1.47 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -11.87 |
Placebo | -4.02 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | 3.03 |
Placebo | -0.29 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -13.48 |
Placebo | -10.35 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -1.44 |
Placebo | -0.01 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -11.20 |
Placebo | -0.80 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -1.48 |
Placebo | -1.52 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -1.97 |
Placebo | -2.40 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent (Least Squares Mean) |
---|---|
NB32 | -0.63 |
Placebo | -0.14 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -20.91 |
Placebo | -13.29 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -20.56 |
Placebo | -14.67 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 0.01 |
Placebo | -1.60 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 9.27 |
Placebo | 7.90 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -11.89 |
Placebo | -6.91 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB32 | 0.03 |
Placebo | -1.12 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | cm (Least Squares Mean) |
---|---|
NB32 | -4.97 |
Placebo | -2.89 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB32 | -5.03 |
Placebo | -1.75 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 44.53 |
Placebo | 18.87 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 20.72 |
Placebo | 10.22 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 44.14 |
Placebo | 26.28 |
Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control. (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 0 |
Placebo | 1.89 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 22.26 |
Placebo | 35.22 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 3.02 |
Placebo | 1.26 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 1.89 |
Placebo | 1.26 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | kg (Least Squares Mean) |
---|---|
NB + CLI | -9.7 |
Usual Care | -1.0 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | uIU/mL (Least Squares Mean) |
---|---|
NB + CLI | -7.5 |
Usual Care | -3.4 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB + CLI | -1.7 |
Usual Care | -1.3 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | 4.1 |
Usual Care | 0.1 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | -2.0 |
Usual Care | -1.9 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | -2.9 |
Usual Care | 1.6 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | -13.6 |
Usual Care | 2.8 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | bpm (Least Squares Mean) |
---|---|
NB + CLI | 1.7 |
Usual Care | -0.3 |
HOMA-IR is an insulin sensitivity index that is calculated as HOMA-IR = (Glucose * Insulin) / 405, where glucose is in mass units (mg/dL) and insulin is in µIU/mL. Higher values indicate lower insulin sensitivity. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | -2.0 |
Usual Care | -0.8 |
Arizona Sexual Experiences (ASEX) scale is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | -2.2 |
Usual Care | -0.1 |
The BES is a 16-item questionnaire that identifies different levels of binge-eating severity, with total scores ranging between 0-46. BES scores were categorized as follows: None = Scores ≤17 indicated no significant binge eating, Moderate = scores from 18 to 26 (inclusive), Severe = scores ≥27 indicated severe levels of binge eating. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | -6.8 |
Usual Care | 1.1 |
Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) is a self-reported assessment of perceived effect of weight on quality of life. It consists of 31 items organized in 5 domains (physical function, self-esteem, sexual life, public distress and work). IWQOL-Lite total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | 16.4 |
Usual Care | -1.0 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB + CLI | -4.8 |
Usual Care | -2.8 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | cm (Least Squares Mean) |
---|---|
NB + CLI | -6.96 |
Usual Care | -1.64 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percent change in body weight (Least Squares Mean) |
---|---|
NB + CLI | -9.46 |
Usual Care | -0.94 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percentage of participants (Number) |
---|---|
NB + CLI | 42.3 |
Usual Care | 3.7 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percentage of participants (Number) |
---|---|
NB + CLI | 12.7 |
Usual Care | 0.0 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percentage of participants (Number) |
---|---|
NB + CLI | 84.5 |
Usual Care | 12.2 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 41.49 |
Placebo | 20.21 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | mmHg (Least Squares Mean) |
---|---|
NB32 | -1.41 |
Placebo | -2.78 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -2.36 |
Placebo | -1.08 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | 4.10 |
Placebo | 0.87 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -27.98 |
Placebo | -15.45 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | 5.43 |
Placebo | 8.13 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -16.62 |
Placebo | -8.51 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -2.06 |
Placebo | -1.97 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -2.54 |
Placebo | -2.43 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -25.87 |
Placebo | -16.89 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -29.93 |
Placebo | -16.56 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 0.09 |
Placebo | -0.00 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 13.43 |
Placebo | 10.29 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -13.75 |
Placebo | -8.46 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | mmHg (Least Squares Mean) |
---|---|
NB32 | -1.32 |
Placebo | -3.87 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | cm (Least Squares Mean) |
---|---|
NB32 | -9.98 |
Placebo | -6.77 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB32 | -9.29 |
Placebo | -5.08 |
(NCT00456521)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 66.39 |
Placebo | 42.49 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | Percentage of participants (Number) |
---|---|
NB16 | 20.17 |
NB32 | 24.63 |
Placebo | 7.44 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB16 | 0.09 |
NB32 | 0.04 |
Placebo | -0.86 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB16 | -2.39 |
NB32 | -3.24 |
Placebo | -1.30 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB16 | 3.36 |
NB32 | 3.42 |
Placebo | -0.06 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB16 | -11.84 |
NB32 | -17.14 |
Placebo | -4.57 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB16 | -3.67 |
NB32 | -4.41 |
Placebo | -3.28 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB16 | -7.96 |
NB32 | -12.69 |
Placebo | -3.08 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB16 | -1.85 |
NB32 | -2.11 |
Placebo | -1.84 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB16 | -2.08 |
NB32 | -2.62 |
Placebo | -2.77 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB16 | -28.02 |
NB32 | -28.98 |
Placebo | -16.66 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB16 | -14.33 |
NB32 | -20.19 |
Placebo | -5.90 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB16 | 0.02 |
NB32 | -0.27 |
Placebo | -0.72 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB16 | 11.68 |
NB32 | 12.69 |
Placebo | 8.55 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB16 | -12.49 |
NB32 | -14.52 |
Placebo | -8.68 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB16 | 0.29 |
NB32 | -0.11 |
Placebo | -1.94 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | cm (Least Squares Mean) |
---|---|
NB16 | -5.04 |
NB32 | -6.24 |
Placebo | -2.46 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB16 | -5.00 |
NB32 | -6.14 |
Placebo | -1.33 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB16 | 39.49 |
NB32 | 47.98 |
Placebo | 16.44 |
23 reviews available for bupropion and Weight Loss
Article | Year |
---|---|
Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis.
Topics: Adult; Bupropion; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Recept | 2023 |
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
Topics: Anti-Obesity Agents; Bupropion; Epidemics; Global Health; Humans; Liraglutide; Naltrexone; Obesity; | 2020 |
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orl | 2021 |
Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses.
Topics: Bupropion; Child; Female; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Smoking C | 2021 |
Gender-related issues in the pharmacology of new anti-obesity drugs.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; F | 2019 |
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
Topics: Androgens; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Insulin Resistance; Li | 2018 |
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Drug Therapy, Combination; Energy Metabolism; H | 2014 |
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Nal | 2014 |
Overview of new antiobesity drugs.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Li | 2014 |
Safety and tolerability of medications approved for chronic weight management.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects | 2015 |
Current and emerging medications for overweight or obesity in people with comorbidities.
Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidem | 2015 |
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes.
Topics: Adult; Anti-Obesity Agents; Bupropion; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Naltrex | 2016 |
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations | 2016 |
Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity.
Topics: Animals; Bupropion; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Drug Therapy, Co | 2009 |
Naltrexone for the treatment of obesity: review and update.
Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Feeding Behavior; Humans; | 2009 |
Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
Topics: Administration, Oral; Animals; Appetite; Bupropion; Controlled Clinical Trials as Topic; Delayed-Act | 2009 |
Pharmacologic therapies for obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; | 2010 |
Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?
Topics: Bupropion; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type | 2011 |
Combination therapy with naltrexone and bupropion for obesity.
Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Humans; Naltrexone; Narcotic Anta | 2011 |
Naltrexone/bupropion: an investigational combination for weight loss and maintenance.
Topics: Anti-Obesity Agents; Bupropion; Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; H | 2011 |
ACS chemical neuroscience molecule spotlight on contrave.
Topics: Anti-Obesity Agents; Bupropion; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Appro | 2011 |
Recent advancements in drug treatment of obesity.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinati | 2012 |
Bupropion for weight reduction.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Dose-Response Relatio | 2007 |
19 trials available for bupropion and Weight Loss
Article | Year |
---|---|
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial.
Topics: Behavior Therapy; Binge-Eating Disorder; Bupropion; Double-Blind Method; Female; Humans; Male; Middl | 2022 |
An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder.
Topics: Binge-Eating Disorder; Bupropion; Case-Control Studies; Feeding Behavior; Humans; Naltrexone; Weight | 2021 |
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamin | 2013 |
Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Body Mass Index; Bulimia; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; | 2013 |
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight; Bupro | 2013 |
Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity.
Topics: Adult; Aged; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Male; Middle Aged; N | 2015 |
The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.
Topics: Adolescent; Adult; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Humans; Male; | 2016 |
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Bupropion; Combined Modality Therapy; Delayed-Action Pr | 2016 |
Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
Topics: Adolescent; Adult; Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; | 2017 |
Rational design of a combination medication for the treatment of obesity.
Topics: Adult; Animal Feed; Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Drug Therapy, | 2009 |
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
Topics: Adolescent; Adult; Appetite; Bupropion; Cohort Studies; Dopamine Uptake Inhibitors; Double-Blind Met | 2009 |
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality | 2011 |
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality | 2011 |
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality | 2011 |
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.
Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality | 2011 |
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adult; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Double-Blind Method; Drug Therap | 2010 |
Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study.
Topics: Adult; Antidepressive Agents; Binge-Eating Disorder; Body Mass Index; Bupropion; Depressive Disorder | 2012 |
Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Bupropion; Cholesterol; Delayed-Action Prepa | 2002 |
Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Buprop | 2006 |
Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.
Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Huma | 2007 |
Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.
Topics: Adult; Anti-Obesity Agents; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Adminis | 2001 |
Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Body Constitution; Bupropion; Cholesterol, HDL; De | 2002 |
20 other studies available for bupropion and Weight Loss
Article | Year |
---|---|
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long
Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Human | 2023 |
Naltrexone-bupropion for weight loss.
Topics: Bupropion; Humans; Naltrexone; Weight Loss | 2023 |
Topics: Bupropion; Humans; Naltrexone; Weight Loss | 2023 |
Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study.
Topics: Bupropion; Genotype; Humans; Naltrexone; Pilot Projects; Polymorphism, Single Nucleotide; Protein Se | 2021 |
[Pharmacotherapy for obesity].
Topics: Anti-Obesity Agents; Bariatric Surgery; Bupropion; Combined Modality Therapy; Drug Combinations; Dru | 2021 |
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
Topics: Aged; Anti-Obesity Agents; Body Weight; Bupropion; Diabetes Mellitus, Type 2; Female; Humans; Hypogl | 2021 |
Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample.
Topics: Adult; Bupropion; Clinical Trials, Phase III as Topic; Craving; Dopamine Uptake Inhibitors; Feeding | 2017 |
Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK.
Topics: Anti-Obesity Agents; Bariatric Surgery; Body Weight Maintenance; Bupropion; Health Services; Humans; | 2018 |
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.
Topics: Absorptiometry, Photon; Adiposity; Analysis of Variance; Body Composition; Bupropion; Dopamine Uptak | 2013 |
Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues.
Topics: Adolescent; Adult; Appetite; Bupropion; Cues; Diet; Dopamine Uptake Inhibitors; Drug Therapy, Combin | 2014 |
Contrave--a combination of bupropion and naltrexone for weight loss.
Topics: Anti-Obesity Agents; Bupropion; Drug Approval; Drug Combinations; Drug Interactions; Humans; Naltrex | 2014 |
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesit | 2014 |
D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.
Topics: Action Potentials; Animals; Appetite Depressants; Benzazepines; Bupropion; Diethylpropion; Dopamine | 2015 |
Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.
Topics: Anti-Obesity Agents; Blood Pressure; Bupropion; Drug Combinations; Drug Interactions; Humans; Mental | 2015 |
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones | 2016 |
Improving efficacy of the adjustable gastric band: studies of the use of adjuvant approaches in a rodent model.
Topics: Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Blood Glucose; Body Composition; Body Fat Distr | 2017 |
Obesity Epidemic: Pharmaceutical Weight Loss.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; | 2017 |
Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination?
Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Body Mass Index; Bupropion; Delayed-Action Preparation | 2010 |
What cost weight loss?
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; P | 2012 |
Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis.
Topics: Animals; Area Under Curve; Behavior, Animal; Bupropion; Catecholamines; Dopamine Uptake Inhibitors; | 2008 |